文献速递药物不良反应与药物警戒

抗精神病药与锂盐致睡行症的安全信号:药物警戒不相称性分析

A safety signal of somnambulism with the use of antipsychotics and lithium: A pharmacovigilance disproportionality analysis.
PubMed 文献 · Br J Clin Pharmacol · 2021-03-27

基于VigiBase数据库的药物警戒不相称性分析,评估抗精神病药与锂盐相关睡行症或睡眠相关进食障碍(SRED)的报告风险。共5784例睡行症或SRED报告中508例涉及至少一种抗精神病药或锂盐,第二代抗精神病药(PRR 3.44)和锂盐(PRR 2.03)呈显著关联,第一代抗精神病药无显著关联。

要点

  • 第二代抗精神病药与睡行症或SRED报告呈显著不相称性信号(PRR 3.44)。
  • 锂盐亦呈显著信号(PRR 2.03),第一代抗精神病药无显著关联。
  • 涉及病例中53.3%怀疑喹硫平,几乎所有第二代抗精神病药均有关联。

核心结论

  • 第二代抗精神病药和锂盐与睡行症或SRED报告存在显著不相称性安全信号。
  • 第一代抗精神病药与睡行症或SRED报告无显著关联。

研究设计与样本

  • 识别所有与抗精神病药或锂盐相关的睡行症或SRED报告,计算报告比值比(PRR)和信息成分。

主要发现

  • 5784例睡行症或SRED报告中,508例至少怀疑一种抗精神病药或锂盐。
  • 涉及病例中大多数患者年龄18-64岁(62.0%),男性占37.0%。
  • 77.6%的病例中抗精神病药或锂盐是唯一涉及的药物类别,53.3%的病例怀疑喹硫平。
  • 睡行症报告占88.6%,SRED占18.1%。
  • 第二代抗精神病药PRR 3.44(95%CI 3.13),锂盐PRR 2.03(95%CI 1.22-3.37),第一代抗精神病药PRR 0.99(95%CI 0.68-1.44)。

关键数值与推荐

  • 第二代抗精神病药PRR 3.44(95%CI 3.13),提示显著不相称性信号。
  • 锂盐PRR 2.03(95%CI 1.22-3.37),提示显著不相称性信号。
  • 第一代抗精神病药PRR 0.99(95%CI 0.68-1.44),无显著关联。

临床怎么用

  • 临床使用第二代抗精神病药或锂盐时,应关注患者是否出现睡行症或睡眠相关进食障碍。
  • 对报告睡行症或SRED的患者,评估用药史时需考虑第二代抗精神病药和锂盐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Antipsychotics and lithium are widely used in psychiatry, particularly in schizophrenia and bipolar disorders. Recently, some cases of somnambulism or sleep-related eating disorder (SRED) have been reported in patients treated with these drugs. This study investigated the risk of reporting somnambulism or SRED associated with the use of antipsychotics and lithium. METHODS: The World Health Organization pharmacovigilance database (VigiBase), comprising >18 million adverse events, was queried. All somnambulism or SRED reports related to antipsychotics or lithium were identified. The association between antipsychotics or lithium and somnambulism or SRED was computed using the proportional reporting ratio (PRR) and information component. RESULTS: Among the 5784 cases reporting somnambulism or SRED, 508 suspected at least 1 antipsychotic or lithium. Most patients were aged 18-64 years (62.0%), and 37.0% were men. In most cases (77.6%), antipsychotic or lithium were the only drug class involved, and 53.3% of cases suspected quetiapine. Somnambulism was reported in 88.6% of cases and SRED in 18.1%. A significant association was found for second-generation antipsychotics (PRR 3.44, 95% confidence interval 3.13) and lithium (PRR 2.03, [1.22; 3.37]), but not for first-generation antipsychotics (PRR 0.99, [0.68; 1.44]). CONCLUSIONS: We found a significant signal of somnambulism or SRED related to second-generation antipsychotics and lithium. While case reports mentioned mostly quetiapine and olanzapine, almost all second-generation antipsychotics were associated with somnambulism or SRED.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Gouverneur A, Ferreira A, Morival C, et al. A safety signal of somnambulism with the use of antipsychotics and lithium: A pharmacovigilance disproportionality analysis. Br J Clin Pharmacol. 2021. PMID: 33713370. doi:10.1111/bcp.14818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。